xtremepicks.com: www.Xtremepicks.Com: Xtremepicks Alerts November 18, 2009 : DSTI, AATI, SHMR and ALNY

DayStar Technologies, Inc. (Nasdaq: DSTI | Quote | Chart | News | PowerRating) trading at $0.50 per share on trading volume of 782,984 shares.

In a press release out on November 18, DayStar Technologies Announces Appointment of Dr. Kang Sun to Board of Directors

SANTA CLARA, Calif., Nov 18, 2009 -- DayStar Technologies, Inc. (Nasdaq: DSTI), a developer of solar photovoltaic products based on CIGS thin-film deposition technology, announced today that its board of directors has appointed Dr. Kang Sun, Ph.D. as an independent director of the board of directors of the company, effective immediately.

About DayStar Technologies, Inc.

DayStar Technologies, Inc. is engaged in the development, manufacturing and marketing of solar photovoltaic products based upon CIGS thin film deposition technology. For more information, visit the DayStar website at www.daystartech.com.

Advanced Analogic Technologies, Inc. (Nasdaq: AATI | Quote | Chart | News | PowerRating) trading at $3.05 per share on trading volume of 202,982 shares.

In a press release out on November 18, AnalogicTech(TM) Launches Family of Direct and Edge LED Backlighting Drivers; Unveils Strategic Roadmap for LED Backlit LCD Televisions

SANTA CLARA, Calif., Nov 18, 2009 -- As part of its market expansion and diversification strategy, Advanced Analogic Technologies, Inc. (AnalogicTech) (Nasdaq: AATI), an analog semiconductor company focused on powering innovative solutions in consumer, industrial, and communications markets, today made its official move into the LED backlit LCD television market with the first chip set families in a series of innovative power management semiconductor systems designed to significantly enhance energy efficiency and user-experience for LED backlit LCD televisions.

About Advanced Analogic Technologies, Inc:

Advanced Analogic Technologies, Inc. (AnalogicTech) (NASDAQ: AATI | Quote | Chart | News | PowerRating) develops advanced semiconductor system solutions that play a key role in the continuing evolution of feature-rich, energy efficient electronic devices. The company focuses on addressing the application-specific power management needs of consumer devices such as mobile handsets, digital cameras, and netbooks/notebooks, as well as devices in a broad range of industrial, medical and telecom applications. AnalogicTech also licenses device, process, package, and application-related technologies. Headquartered in Silicon Valley, AnalogicTech has design centers in Santa Clara and Shanghai, and Asia-based operations and logistics. For more information, please visitwww.analogictech.com (AnalogicTech - G).

Shamir Optical Industry Ltd. (Nasdaq: SHMR | Quote | Chart | News | PowerRating) trading at $8.35 on a volume of 3,473 shares

In a press release out on November 18, Shamir Optical Industry Ltd. Reports Third Quarter 2009 Results

--Operating Income Increased 64.3% in the Quarter--Purchased Controlling Stake in Australian Lab

KIBBUTZ SHAMIR, Israel, Nov 18, 2009 -- Shamir Optical Industry Ltd. (Nasdaq: SHMR | Quote | Chart | News | PowerRating) ("Shamir"), a leading provider of innovative products and technology to the ophthalmic lens market, today announced unaudited financial results for the third quarter ended September 30, 2009.

About Shamir

Shamir is a leading provider of innovative products and technology to the spectacle lens market. Utilizing its proprietary technology, the company develops, designs, manufactures, and markets progressive lenses to sell to the ophthalmic market. In addition, Shamir utilizes its technology to provide design services to optical lens manufacturers under service and royalty agreements. Progressive lenses are used to treat presbyopia, a vision condition where the eye loses its ability to focus on close objects. Progressive lenses combine several optical strengths into a single lens to provide a gradual and seamless transition from near to intermediate, to distant vision. Shamir differentiates its products from its competitors' primarily through lens design. Shamir's leading lenses are marketed under a variety of trade names, including Shamir Genesis(TM), Shamir Piccolo(TM), Shamir Office(TM), Shamir Nano(TM), Shamir Autograph(TM) and Shamir Smart(TM). Shamir believes that it has one of the world's preeminent research and development teams for progressive lenses, molds, and complementary technologies and tools. Shamir developed software dedicated to the design of progressive lenses. This software is based on Shamir's proprietary mathematical algorithms that optimize designs of progressive lenses for a variety of activities and environments. Shamir also has created software tools specifically designed for research and development and production requirements, including Eye Point Technology software, which simulates human vision.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY | Quote | Chart | News | PowerRating) trading at $17.52 on a volume of 39,347 shares

In a press release out on November 18, Alnylam Presents New Pre-clinical Data on ALN-VSP, an RNAi Therapeutic for the Treatment of Liver Cancer

- New Results Demonstrate Robust Anti-Tumor Activity in Multiple Models, Including Extra-Hepatic Tumors -

CAMBRIDGE, Mass., Nov 18, 2009 -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced new pre-clinical data from its ALN-VSP program presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International conference being held November 15 - 19, 2009 in Boston, Mass. ALN-VSP is an RNAi therapeutic currently in a Phase I clinical trial for the treatment of liver cancers, including hepatocellular carcinoma (HCC) and other solid tumors with liver involvement. The new data demonstrated robust anti-tumor activity in orthotopic liver tumor models comprised of both HCC- and colorectal cancer-derived cell lines. ALN-VSP was also shown to act on disseminated tumors outside of the liver. Further, in addition to anti-proliferative effects, studies showed that ALN-VSP exerts a potent anti-angiogenic effect on tumors.

About Alnylam Pharmaceuticals

Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is leading the translation of RNAi as a new class of innovative medicines with peer-reviewed research efforts published in the world's top scientific journals including Nature, Nature Medicine, and Cell. The company is leveraging these capabilities to build a broad pipeline of RNAi therapeutics; its most advanced program is in Phase II human clinical trials for the treatment of respiratory syncytial virus (RSV) infection and is partnered with Cubist and Kyowa Hakko Kirin. In addition, the company is developing RNAi therapeutics for the treatment of a wide range of disease areas, including liver cancers, hypercholesterolemia, Huntington's disease, and TTR amyloidosis. The company's leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Medtronic, Novartis, Biogen Idec, Roche, Takeda, Kyowa Hakko Kirin, and Cubist. To reflect its outlook for key scientific, clinical, and business initiatives, Alnylam established "RNAi 2010" in January 2008 which includes the company's plan to significantly expand the scope of delivery solutions for RNAi therapeutics, have four or more programs in clinical development, and to form four or more new major business collaborations, all by the end of 2010. Alnylam is a joint owner of Regulus Therapeutics, a joint venture focused on the discovery, development, and commercialization of microRNA therapeutics. Founded in 2002, Alnylam maintains headquarters in Cambridge, Massachusetts. For more information, please visit http://www.alnylam.com.

Xtremepicks.com profiles early stage microcap and growth stocks that provide innovative products or services resulting in potentially "hyper-growth" opportunities. Often, these companies have yet to be recognized by Wall Street and the undiscovered nature of Xtremepicks.com's profile companies provide our members the opportunity to learn about these companies at their development stage, and more importantly before they possibly "turn the corner" and get exposed to a much larger investing audience.

Xtremepicks.com (www.Xtremepicks.com) has prepared all material herein based upon information believed to be reliable. The information contained herein is not guaranteed by Xtremepicks.com to be accurate, and should not be considered to be all-inclusive. Xtremepicks.com is a leading information resource for evaluating investment opportunities in small and microcap stocks. We focus on a limited number of companies in order to provide comprehensive coverage, including unique investment related features not available anywhere else on the Internet. To feature a company or to get more information, please visit us at www.Xtremepicks.com or email us at info@Xtremepicks.com Xtremepicks.coms affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event of a rise in value. Xtremepicks.com will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

To view full disclaimers, go to http://www.Xtremepicks.com/disclaimer.htm

CONTACT: Xtremepicks.com
e-mail: Info@xtremepicks.com
WWW: http://www.Xtremepicks.com

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

For full details on Advanced Analogic Technologies Inc (AATI) AATI. Advanced Analogic Technologies Inc (AATI) has Short Term PowerRatings at TradingMarkets. Details on Advanced Analogic Technologies Inc (AATI) Short Term PowerRatings is available at This Link.

For full details on Alnylam Pharmaceuticals (ALNY) ALNY. Alnylam Pharmaceuticals (ALNY) has Short Term PowerRatings at TradingMarkets. Details on Alnylam Pharmaceuticals (ALNY) Short Term PowerRatings is available at This Link.

For full details on Daystar Technologies Inc (DSTI) DSTI. Daystar Technologies Inc (DSTI) has Short Term PowerRatings at TradingMarkets. Details on Daystar Technologies Inc (DSTI) Short Term PowerRatings is available at This Link.

For full details on Shamir Optical Industry Ltd (SHMR) SHMR. Shamir Optical Industry Ltd (SHMR) has Short Term PowerRatings at TradingMarkets. Details on Shamir Optical Industry Ltd (SHMR) Short Term PowerRatings is available at This Link.